{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:03:40Z","timestamp":1789473820291,"version":"build-2803163510"},"reference-count":21,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2013,3]]},"abstract":"\n OBJECTIVE<\/jats:title>\n To review the pharmacology, efficacy, and safety of phentermine\/topiramate (PHEN\/TPM) in the management of obese patients.<\/jats:p>\n <\/jats:sec>\n \n DATA SOURCES<\/jats:title>\n MEDLINE (1966-July 2012) was searched using the terms weight loss, obesity, phentermine and topiramate, phentermine, topiramate, Qnexa, Qsymia, and VI-0521. Additionally, the new drug application and prescribing information for PHEN\/TPM were retrieved.<\/jats:p>\n <\/jats:sec>\n \n STUDY SELECTION\/DATA EXTRACTION<\/jats:title>\n All studies considering the pharmacology, efficacy, and safety of PHEN\/TPM were reviewed with a focus on efficacy and safety data from Phase 3 trials.<\/jats:p>\n <\/jats:sec>\n \n DATA SYNTHESIS<\/jats:title>\n In 3 Phase 3 trials (EQUIP, CONQUER, and SEQUEL), treatment with PHEN\/TPM consistently demonstrated statistically significant weight loss compared with placebo. After 56 weeks of treatment, percent weight loss achieved with PHEN\/TPM was 10.6%, 8.4%, and 5.1% with 15\/92 mg, 7.5\/46 mg, and 3.75\/23 mg, respectively (p < 0.0001). The 52-week extension study (SEQUEL) showed maintained weight loss over 2 years with 9.3% and 10.5% weight loss from baseline for 7.5\/46 mg and 15\/92 mg PHEN\/TPM (p < 0.0001). A significantly higher proportion of patients achieved greater than 5%, 10%, or 15% weight loss with PHEN\/TPM compared with placebo. Significant reductions in waist circumference, fasting triglycerides, and fasting glucoses were also attributable to PHEN\/TPM. The drug was generally well tolerated in clinical trials. Adverse reactions occurring in 5% or more of study subjects included paresthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth.<\/jats:p>\n <\/jats:sec>\n \n CONCLUSIONS<\/jats:title>\n PHEN\/TPM is a new, once-daily, controlled-release, combination weight-loss product approved as an adjunct to diet and exercise for chronic weight management of obese or overweight patients with weight-related comorbidities. PHEN\/TPM is modestly effective and a viable option for patients interested in losing weight, although long-term safety data are lacking.<\/jats:p>\n <\/jats:sec>","DOI":"10.1345\/aph.1r501","type":"journal-article","created":{"date-parts":[[2013,3,12]],"date-time":"2013-03-12T23:07:31Z","timestamp":1363129651000},"page":"340-349","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":105,"title":["Phentermine\/Topiramate for the Treatment of Obesity"],"prefix":"10.1177","volume":"47","author":[{"given":"Steven M","family":"Smith","sequence":"first","affiliation":[{"name":"Steven M Smith PharmD MPH, Assistant Professor, Department of Clinical Pharmacy, School of Pharmacy, University of Colorado, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Meyer","sequence":"additional","affiliation":[{"name":"Melissa Meyer PharmD, Pharmacy Practice Resident, Exempla Saint Joseph Hospital, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy E","family":"Trinkley","sequence":"additional","affiliation":[{"name":"Katy E Trinkley PharmD, Assistant Professor, Department of Clinical Pharmacy, School of Pharmacy, University of Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,12,21]]},"reference":[{"key":"bibr1-aph.1R501","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.39"},{"key":"bibr2-aph.1R501","unstructured":"2 Centers for Disease Control and Prevention. Obesity and overweight for professionals: childhood data. www.cdc.gov\/obesity\/data\/childhood.html (accessed 2012 Jul 21)."},{"key":"bibr3-aph.1R501","unstructured":"3 National Heart, Lung, and Blood Institute (NHLBI). Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults, 1998. www.nhlbi.nih.gov\/guidelines\/obesity\/ob_gdlns.pdf (accessed 2012 Aug 20)."},{"key":"bibr4-aph.1R501","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.2014"},{"key":"bibr5-aph.1R501","unstructured":"5 Qnexa New Drug Application. Department of Health and Human Services: 2010. www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM292317.pdf (accessed 2012 Jul 10)."},{"key":"bibr6-aph.1R501","unstructured":"6 Food and Drug Administration. FDA drug safety communication: completed safety review of Xenical\/Alli (orlistat) and severe liver injury. www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm213038.htm (accessed 2012 Jul 20)."},{"key":"bibr7-aph.1R501","volume-title":"Product information. Adipex-p (phentermine)","year":"2005"},{"key":"bibr8-aph.1R501","first-page":"289","volume":"16","author":"Langlois KJ","year":"1974","journal-title":"Curr Ther Res"},{"key":"bibr9-aph.1R501","volume-title":"Product information. Qsymia (phentermine\/topiramate)","year":"2012"},{"key":"bibr10-aph.1R501","volume-title":"Product information. Topamax (topiramate)","year":"2009"},{"key":"bibr11-aph.1R501","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2003.78"},{"key":"bibr12-aph.1R501","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2011.330"},{"key":"bibr13-aph.1R501","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60205-5"},{"key":"bibr14-aph.1R501","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.111.024927"},{"key":"bibr15-aph.1R501","volume-title":"The LEARN program for weight management","author":"Brownell KD","year":"2004","edition":"10"},{"key":"bibr16-aph.1R501","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.7.826"},{"key":"bibr17-aph.1R501","unstructured":"17 Product information. Qsymia (phentermine\/topiramate CR). www.qsymia.com\/hcp\/ (accessed 2012 Sept 21)."},{"key":"bibr18-aph.1R501","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.1.155"},{"key":"bibr19-aph.1R501","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909809"},{"key":"bibr20-aph.1R501","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp100638"},{"key":"bibr21-aph.1R501","volume-title":"Micromedex Healthcare Series"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1R501","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1R501","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1R501","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:12:41Z","timestamp":1777374761000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1R501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10.1345\/aph.1R501"],"URL":"https:\/\/doi.org\/10.1345\/aph.1r501","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}